Symbols

VRDN

Viridian·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VRDN

Viridian Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing drugs for autoimmune disease and thyroid eye disease

Industry

Pharmaceutical

Established Date

06/17/2014

Listing Date

06/18/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

143

Fiscal Year Ends

12-31

Website

www.viridiantherapeutics.com

Security Type

Common stock

Office address

221 Crescent Street, Suite 401, Waltham, MA 02453

Business

Introduction

Founded in Delaware on June 17, 2014, Viridian Therapeutics, Inc., is a biopharmaceutical company focused on the research and development of potentially optimal medicines for serious and rare diseases. The company is targeting less competitive disease areas where marketed therapies often leave room for improved efficacy, safety or ease of administration. The company believes that first-generation drugs rarely represent the best solution, especially in the field of rare diseases, and have the potential to develop differentiated, best-in-class drugs that improve patient outcomes, reduce side effects, improve quality of life, expand market access and enhance market competition. The company is developing three product candidates: VRDN-001, VRDN-002 and VRDN-003, which are under development for intravenous or subcutaneous injection to treat patients with thyroid eye disease (TED). The company's most advanced project, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R for the treatment of TED.

Company Financials

EPS

VRDN has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -0.94, beating expectations. The chart below visualizes how VRDN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VRDN has released its 2025 Q3 earnings report, with revenue of 70.57M, reflecting a YoY change of 81958.14%, and net profit of -34.60M, showing a YoY change of 54.88%. The Sankey diagram below clearly presents VRDN's revenue sources and cost distribution.